- Home
- AGCC vs CTNM Comparison
AGCC vs CTNM Comparison
Compare AGCC & CTNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | AGCC | CTNM |
|---|---|---|
| Founded | 2020 | 2009 |
| Country | Taiwan | United States |
| Employees | N/A | N/A |
| Industry | Beverages (Production/Distribution) | |
| Sector | Consumer Staples | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 660.6M | 550.7M |
| IPO Year | 2025 | 2024 |
Fundamental Metrics
Financial Performance| Metric | AGCC | CTNM |
|---|---|---|
| Price | $15.01 | $9.39 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $22.14 |
| AVG Volume (30 Days) | 4.0K | ★ 1.2M |
| Earning Date | 11-13-2026 | 11-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 0.46 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $168.97 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $4.72 | $6.73 |
| 52 Week High | $25.73 | $17.79 |
Technical Indicators
Market Signals| Indicator | AGCC | CTNM |
|---|---|---|
| Relative Strength Index (RSI) | 51.08 | 43.03 |
| Support Level | $14.17 | $6.73 |
| Resistance Level | $15.94 | $13.72 |
| Average True Range (ATR) | 0.89 | 0.80 |
| MACD | -0.07 | 0.27 |
| Stochastic Oscillator | 46.40 | 83.60 |
Price Performance
Historical ComparisonAbout AGCC Agencia Comercial Spirits Ltd Class A Ordinary Shares
Agencia Comercial Spirits Ltd specializes in the procurement, distribution, and sale of high-quality whiskies, including both bottled and cask whisky in both Taiwan and international markets. The company's product portfolio includes the distribution of bottled whisky, raw cask whisky, and proprietary brand whisky.
About CTNM Contineum Therapeutics Inc.
Contineum Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the development of oral small-molecule therapies for neurological, inflammatory, and immunological conditions. The company focuses on developing selective compounds targeting challenging molecular pathways and has built a portfolio of small molecule drug candidates. Its pipeline includes drug candidates in clinical development, such as PIPE-791, an LPA1 receptor antagonist being studied for idiopathic pulmonary fibrosis and chronic pain, and PIPE-307, an M1 receptor inhibitor being evaluated for relapsing-remitting multiple sclerosis and other depressive disorders.